Quest Diagnostics Incorporated (DGX) Q2 2022 Earnings Results

Quest Diagnostics Beats on EPS, Stock Down 0.16%

Quest Diagnostics reported a better-than-expected EPS, which indicates some resilience in profitability. However, the stock reacted slightly negatively, down 0.16%, suggesting that investors may have been looking for more comprehensive insights or guidance that was not provided.

The print

Key numbers

Actual vs. consensus

Metric	Actual	Expected	Surprise
EPS	$2.36	N/A	+6.12%
Revenue	N/A	N/A	N/A

Management

Management commentary

Tone: Unknown

No transcript is on record, and the analysis is based on numerical results only.

Quest Diagnostics Beats on EPS, Stock Down 0.16%

Key numbers

Management commentary

Quest Diagnostics Incorporated

More earnings this week

Quest Diagnostics Beats on EPS, Stock Down 0.16%

Key numbers

Management commentary